Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions - Takeaways - MDSpire

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions

  • By

  • Ya Chen

  • Tianyou Ma

  • Congcong Zhu

  • Zongguang Tai

  • Huijun Pan

  • Zhongjian Chen

  • Quangang Zhu

  • April 24, 2026

  • 0 min

Share

  • 1

    Solanum nigrum (SN) has been traditionally used to treat psoriasis, but its therapeutic mechanisms and active compounds were previously unclear.

  • 2

    The study found that NLRP3 inflammasome activation is elevated in psoriatic lesions, implicating it in the disease's pathogenesis.

  • 3

    SN significantly reduced disease severity in psoriasis models by inhibiting NLRP3 inflammasome activation and lowering inflammatory cytokines.

  • 4

    Transcriptomic analysis revealed that SN primarily modulates PRR/NLR-related signaling pathways associated with psoriasis.

  • 5

    Trigonelline was identified as a key bioactive component of SN contributing to its anti-psoriatic effects, supporting its therapeutic application.

Original Source(s)

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions

  • by Ya Chen, Tianyou Ma, Congcong Zhu, Zongguang Tai, Huijun Pan, Zhongjian Chen, Quangang Zhu

  • April 24, 2026

Related Content

Survey on Real-World Interventions and Strategies for Treat-to-Target Approaches in Psoriasis Management in Canada

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review